Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

Gettinger, S.Borghaei, H.Brahmer, J.Chow, L.Burgio, M.De Castro Carpeno, J.Pluzanski, A.Arrieta, O.Aren Frontera, O.Chiari, R.Butts, C.Wojcik-Tomaszewska, J.Coudert, B.Garassino, M.Ready, N.Felip, E.Alonso Garcia, M.Waterhouse, D.Domine, M.Barlesi, F.Antonia, S.Wohlleber, M.Gerber, D.Czyzewicz, G.Spigel, D.Crino, L.Eberhardt, W.Li, A.Marimuthu, S.Vokes, E.2025-01-072025-01-072019-10-011556-0864https://hdl.handle.net/10668/27253ennivolumab5-year overall survivaladvanced non-small cell lung cancerFive-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLCconference outputopen access10.1016/j.jtho.2019.08.4861556-1380http://www.jto.org/article/S1556086419311694/pdf492162201171